HC Wainwright Weighs in on Senseonics FY2030 Earnings

Senseonics Holdings, Inc. (NYSE:SENS) – Stock analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Senseonics in a report issued on Tuesday, March 3rd. HC Wainwright analyst S. Lee expects that the company will earn ($1.19) per share for the year. HC Wainwright currently has a “Buy” rating and a $18.50 price target on the stock. The consensus estimate for Senseonics’ current full-year earnings is ($0.14) per share.

A number of other equities research analysts have also commented on the company. Barclays reiterated an “overweight” rating and issued a $31.00 target price (up from $1.50) on shares of Senseonics in a research report on Wednesday, November 5th. Stifel Nicolaus set a $9.00 price objective on shares of Senseonics in a report on Tuesday. Finally, TD Cowen reissued a “buy” rating on shares of Senseonics in a report on Thursday, January 8th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Senseonics currently has a consensus rating of “Buy” and a consensus price target of $22.70.

Senseonics Stock Up 0.7%

Shares of SENS stock opened at $6.87 on Wednesday. Senseonics has a fifty-two week low of $5.25 and a fifty-two week high of $15.74. The firm has a market capitalization of $280.70 million, a PE ratio of -52.85 and a beta of 0.99. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The stock’s 50-day simple moving average is $7.20 and its 200-day simple moving average is $7.55.

Institutional Investors Weigh In On Senseonics

Several hedge funds have recently modified their holdings of the company. Smith Salley Wealth Management grew its position in shares of Senseonics by 10.9% during the 3rd quarter. Smith Salley Wealth Management now owns 61,000 shares of the company’s stock valued at $27,000 after acquiring an additional 6,000 shares during the period. HBK Sorce Advisory LLC purchased a new position in Senseonics during the third quarter worth approximately $39,000. Ausdal Financial Partners Inc. grew its holdings in Senseonics by 50.0% in the third quarter. Ausdal Financial Partners Inc. now owns 105,000 shares of the company’s stock valued at $46,000 after purchasing an additional 35,000 shares during the period. Goldstone Financial Group LLC purchased a new stake in shares of Senseonics in the third quarter valued at approximately $52,000. Finally, Townsend Asset Management Corp NC ADV acquired a new position in shares of Senseonics during the 4th quarter worth approximately $60,000. 12.36% of the stock is owned by hedge funds and other institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc is a medical technology company focused on the development and commercialization of innovative continuous glucose monitoring (CGM) systems for people with diabetes. Since its founding in 2011 and headquartered in Germantown, Maryland, the company has pioneered an implantable sensor designed to deliver long-term glucose readings. Senseonics’ mission centers on improving diabetes management by providing accurate, real-time data to patients and healthcare providers.

The company’s flagship offering is the Eversense CGM System, which features a small, fully implantable sensor placed beneath the skin to measure glucose levels for up to 90 days in the United States and up to 180 days in Europe.